Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT06126016 Recruiting - Clinical trials for Secondary Hyperparathyroidism

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Start date: October 19, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis

NCT ID: NCT06120127 Recruiting - Colorectal Cancer Clinical Trials

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence

IMPROVE
Start date: September 25, 2023
Phase: Phase 2
Study type: Interventional

This study is a randomized controlled phase II trial to evaluate the efficacy of the combination of stereotactic body radiation therapy (SBRT) and immunotherapy with postoperative chemotherapy in colorectal cancer liver metastasis (CRLM) patients with high risk of locally recurrence. Researchers will compare the combination therapy with the postoperative chemotherapy alone to see if postoperative chemotherapy plus SBRT and immunotherapy can further reduce the risk of recurrence and metastasis after surgery.

NCT ID: NCT06119581 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

SUNRAY-01
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

NCT ID: NCT06093022 Recruiting - Breast Cancer Clinical Trials

Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study

SurMed-BCLM
Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.

NCT ID: NCT06091683 Recruiting - Clinical trials for Peritoneal Metastases From Colorectal Cancer

Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy to Prevent Colorectal Peritoneal Metastases (ProphyPIPAC)

ProphyPIPAC
Start date: April 30, 2021
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to demonstrate the feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.

NCT ID: NCT06086652 Recruiting - Clinical trials for Metastasis of Unknown Origin

Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

Start date: September 15, 2023
Phase:
Study type: Observational

In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.

NCT ID: NCT06085716 Recruiting - Fatigue Clinical Trials

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Start date: February 16, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.

NCT ID: NCT06083896 Recruiting - Pelvic Metastasis Clinical Trials

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Start date: October 6, 2023
Phase: Phase 1
Study type: Interventional

Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

NCT ID: NCT06081517 Recruiting - Metastatic Cancer Clinical Trials

Evaluating Disparities in Precision Oncology

EDPO
Start date: January 26, 2024
Phase:
Study type: Observational

This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.

NCT ID: NCT06075186 Recruiting - Questionnaire Clinical Trials

Secondary Victim Awareness of Anesthesiologists

Start date: April 1, 2023
Phase:
Study type: Observational [Patient Registry]

Every professional working in the medical field may encounter medical errors and patient safety issues during their careers. Wu, et al. He coined the term 'second victim', which was used for the first time in 2000. In a patient safety incident, the patient is the first to be affected, while the second to be affected are the healthcare professionals (physicians, assistants, nurses, and medical staff) who are the potential causes of the incident and who are adversely affected by the consequences of this incident. That is, secondary victims are characterized as healthcare professionals who are involved in unexpected adverse patient events and experience occupational or psychological difficulties. Almost half of healthcare professionals have been reported to experience the second victim phenomenon during their professional careers. Medical errors or adverse events can deeply affect healthcare professionals and have long-term effects, leading to permanent consequences. In the medical field, identifying the origins of errors plays a vital role in preventing future errors. Second victims can encourage constructive change by not only criticizing the healthcare system but also contributing to the improvement of healthcare institutions. Burlison and his team developed and validated a tool they called the "Second Victim Experience and Support Tool" (SVEST) to understand the coping process of second victims and identify necessary support resources. Koca and colleagues conducted a validation study of the translation and psychometric evaluation of the SVEST (T-SVEST) in Turkey. Our study aims to evaluate the secondary victim experience of anesthesiologists and the quality of support resources.